TITLE:
Alternate-Day Buprenorphine Administration. Phase VII - 8

CONDITION:
Opioid-Related Disorders

INTERVENTION:
Buprenorphine

SUMMARY:

      The purpose of this study is to determine if four times a subjects daily maintenance dose
      will hold for 96 hours without changes in agonist and antagonist effects under open dosing
      conditions.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 21 Years to 48 Years
Criteria:

        Please contact site for information.
      
